Epidemiology and mortality of non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung disease (PF-ILD) using the French national health insurance system (SNDS) database in France: the PROGRESS study

M. Nasser (Lyon, France), S. Larrieu (Bordeaux, France), L. Boussel (Lyon, France), S. Si-Mohamed (Lyon, France), F. Diaz (Bordeaux, France), S. Marque (Bordeaux, France), J. Massol (Bordeaux, France), D. Revel (Lyon, France), F. Thivolet-Bejui (Lyon, France), L. Chalabreysse (Lyon, France), D. Maucort-Boulch (Lyon, France), V. Cottin (Lyon, France)

Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more

Session: Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Session type: E-poster session
Number: 444

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Nasser (Lyon, France), S. Larrieu (Bordeaux, France), L. Boussel (Lyon, France), S. Si-Mohamed (Lyon, France), F. Diaz (Bordeaux, France), S. Marque (Bordeaux, France), J. Massol (Bordeaux, France), D. Revel (Lyon, France), F. Thivolet-Bejui (Lyon, France), L. Chalabreysse (Lyon, France), D. Maucort-Boulch (Lyon, France), V. Cottin (Lyon, France). Epidemiology and mortality of non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung disease (PF-ILD) using the French national health insurance system (SNDS) database in France: the PROGRESS study. 444

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Prevalence and mortality of systemic sclerosis-associated interstitial lung disease (SSc-ILD) using the French national health insurance system (SNDS) database in France Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018
Incidence and prevalence of IPF in an insurance claims database: Assessing accuracy using medical records Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014
Health status & impact of living with idiopathic pulmonary fibrosis (IPF): UK & Ireland Delphi survey Source: International Congress 2016 – IPF clinical Year: 2016
Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017
Incidence of idiopathic pulmonary fibrosis in Italy. Analysis of hospital admission and mortality databases of a large Italian region Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013
Lung function of idiopathic pulmonary fibrosis: Russian IPF registry (Moscow region) Source: International Congress 2019 – Respiratory function assessment in disease Year: 2019
Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016
Central European idiopathic pulmonary fibrosis (IPF) patients survey Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study) Source: Eur Respir J, 57 (2) 2002718; 10.1183/13993003.02718-2020 Year: 2021
Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada Source: Eur Respir J 2016; 48: 187-195 Year: 2016
Prevalence and incidence of interstitial lung diseases (ILDs) in a French multi-ethnic county Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013
Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021
Treatment of idiopathic pulmonary fibrosis (IPF) with nintedanib: an experience from the compassionate use program (CUP) in Estonia Source: International Congress 2017 – Clinical problems in lung diseases Year: 2017
Interims analysis of the EXCITING-ILD registry (registry for exploring clinical and epidemiological characteristics of interstitial lung diseases) Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013
The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea Source: International Congress 2015 – IPF: clinical aspects Year: 2015
Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry Source: Virtual Congress 2020 – Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases Year: 2020
The burden of chronic obstructive pulmonary disease (COPD) in Taiwan Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013